Amvuttra – The Key Growth Driver for Alnylam Amvuttra sales contribute significantly to Alnylam’s top line. The drug generated sales worth $970.5 million in 2024, up 74% on a year-over-year basis.

Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like ...

FDA approved Alnylam's Amvuttra for ATTR-CM, making it the first treatment cleared for both ATTR-CM and hATTR-PN in adults. In trials, Amvuttra cut mortality risk by 36% through 42 months and ...

− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source – − Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality ...

The FDA has signed off on Alnylam’s Amvuttra, also known as vutrisiran, as a treatment for cardiomyopathy of wild-type or hereditary ATTR-CM in adults to reduce the chance of cardiovascular ...

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication. The drug was approved for treatment of the cardiomyopathy of wild-type ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the ...

Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM Pricing strategy crucial for Amvuttra's market share against oral options Alnylam is banking on the success of the drug ...

The market is expected to grow in the coming years, as Alnylam believes the majority of an estimated 150,000 patients in the U.S. remain undiagnosed. Amvuttra’s label is largely similar to its ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of ...